Q3 2023

Filed Nov 9, 2023 · 10-Q · 40 days after period end · 0001615219-23-000071

Q3 2023 · 10-Q

Revenue—

Net Income

-$2.44M

N/M vs Q3 2022

EPS Diluted

-$5.21

N/M vs Q3 2022

Operating Income-$2,532,185N/M

Operating Cash Flowderived-$3,749,026N/M

Same quarter

Metric	Q3 2023	Q3 2022	Q3 2021	Q3 2020
Revenue	—	$0.00	$0.00	$1.38M
Net Income	-$2.44M	-$14.41M	-$3.74M	-$1.72M
EPS Diluted	-$5.21	-$6.41	-$2.09	-$0.10

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR